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DESCRIPTION OF INSULIN RESISTANCE AND BETA CELL 
PANCREAS DYSFUNCTION IN PREDIABETIC PATIENTS 
Abstract.  
Introduction: Prediabetes is the forerunner of diabetes mellitus, hence it has to be 
carefully cared for. Main conditions causing this are insulin resistance and/or beta cell 
dysfunction. Insulin resistance can be assessed by using several methods, one of which is 
performed by assessing the value of HOMA-IR. Beta cell function can be determined by 
assessing HOMA-B. This research aims to obtain description of insulin resistance and 
beta cell pancreas dysfunction on prediabetic patients. Methods: This study is an analytic 
observational study with cross-sectional approach. The HOMA-IR and HOMA-B were 
assessed on 20 prediabetic patients. HOMA-IR and HOMA-B values were obtained by 
examining basal insulin and fasting glucose level. Results: We found man to woman 
ratio 1:1, with mean of age (+/-SD) 35,8 (5,7) years old, BMI 24,9 (4,3) kg/m2, fasting 
blood glucose 104,8 (4,3) mg/dL, and blood glucose two hours after oral glucose 
tolerance test 121,7 (23,1) mg/dl. Mean of HOMA-IR on prediabetic patients was 4,1 
(3,2) and mean of HOMA-B was 188,3 (155,1). Discussion: The increase of insulin 
resistance on this study is in accordance with studies that were conducted by Nguyen 
(2010) and Mohtarin (2016). The increase of HOMA-B in this study is in accordance 
with other studies by Mohtarin (2016) and Owei (2017), supposedly due to beta cell 
compensation process against the increase of insulin resistance. Conclusion: Increase of 
HOMA-IR in prediabetics is compensated for by an increase in HOMA-B. 
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1   Introduction 
Prediabetic is a part of glycometabolic abnormality caused by insulin resistance and/or 
beta cell pancreas dysfunction [1]. During progression of prediabetes, in early phase 
increasing level of blood glucose will be compensated for by increasing level of insulin so that 
glucose uptake will increase. Then, if there are increasing insulin resistance and/or pancreatic 
beta cell dysfunction, glucose uptake will decrease resulting in blood glucose level increase. 
This was described by DeFronzo (2013) using a picture showing mean plasma glucose and 
mean plasma insulin levels during oral glucose tolerance test (OGTT) and insulin mediated 
glucose uptake in five groups of people, namely lean-normoglycemic, obesity-
  
 
 
 
normoglycemic, obesity-impaired glucose tolerance, obesity-diabetes high insulin, and 
obesity-diabetes low insulin people [2].  
Maftin et al. (2010) stated that failure of pancreatic beta cells has been occurred at earlier 
step. Another metabolic research concluded that in impaired glucose tolerance group, there 
have been maximal insulin resistance and losing of beta cell function in more than 80% [3]. 
Prediabetes is diagnosed from laboratory parameter when serum blood glucose is higher 
than normal value, but not high enough for diabetes [4]. Prediabetes consists of impaired 
glucose tolerance (IGT) and impaired fasting glucose (IFG) level. IGT is defined as a 
condition when serum glucose level two hours after oral glucose tolerance test is more than 
140 mg/dL (7,8 mmol/L) but less than 200 mg/dL (11,1 mmol/L), and IFG is defined as a 
condition when fasting blood glucose level is 100 mg/dL (5,6 mmol/L) or more but less than 
126 mg/dL (7,0 mmol/L) [5],[6].  
Centers for Disease Control and Prevention in 2014 presumed that approximately 15-30% 
prediabetic patient will become diabetes in five years. Nowadays, diabetes mellitus is a global 
burden and main health problem in the 21st century. The prevalence has increased in last 
decade. According to International Diabetes Federation Western Pasific Region (WPR) in 
2015, of 415 million population of diabetes in the world, 153 million was found in Western 
Pasific and 10 million in Indonesia [1]. Prediabetic is the forerunner of diabetes mellitus, 
hence it has to be carefully cared for [5],[6]. 
As the main process involved in pathophysiology of prediabetes, insulin resistance and 
beta cell dysfunction need to be assessed. Insulin resistance can be assessed using several 
methods, one of which is the value of HOMA-IR. Cobb etal (2013) concluded that HOMA-IR 
was an important indicator of development of prediabetes and diabetes mellitus [7]. Beta cell 
dysfunction is shown by failure of phase 1 insulin secretion in response to blood glucose. Beta 
cell dysfunction can be determined by assessing the value of HOMA-B. There are many 
studies about the role of HOMA-B in predicting diabetes [8],[9],[10]. This research aims to 
obtain the description of insulin resistance and beta cell pancreas dysfunction on prediabetic 
patients. 
2. Methods 
This research is an analytic observational study with cross-sectional approach, in which 
independent and dependent variabel was assessed at the same time. Research was performed 
on campus of Medical Faculty, Andalas University, Padang, Indonesia for six months. 
Subjects in this research were selected using random sampling method. Inclusion criteria was 
prediabetes with family history of having risk of type 2 diabetes mellitus, while exclusion 
criteria consisted of patient with diabetes mellitus or prediabetes on medication. 
Prediabetics that conform with inclusion and exclusion criteria was 20 patients. Data was 
collected regarding age, sex, body mass index (BMI), fasting blood glucose, and blood 
glucose level two hours after oral glucose tolerance test. These were followed by assessment 
of HOMA-IR and HOMA-B. HOMA-IR was equal to fasting insulin (mU/L) x fasting blood 
  
 
 
 
glucose(mmol/L) divided by 22.5, and HOMA-B was equal to 20 x fasting insulin (mU/L) 
divided by (fasting blood glucose(mmol/L) - 3,5) 
3. Results 
Means and standard deviations of subjects were obtained as follows: age was 35,75 (5,68) 
years, ratio of man to woman was 1:1, mean of BMI was 24,85 (4,25) kg/m2, fasting blood 
glucose was 104,80 (4,25) mg/dL, and blood glucose level two hours after oral glucose 
tolerance test was 121,70 (23,10) mg/dL. Based on age group, most of subject (50%) were in 
31-40 years range, and most of subjects (50%) were in normal BMI group (Table 1). 
 
Table 1. Characteristics of Prediabetic Patient 
Characteristic n (%) Mean (SD) 
Sex   
 Man  10 (50%)  
 Woman  10 (50%)  
Age (year) 
 21-30 
 31-40 
 41-50 
Body mass index (kg/m2) 
 Normoweight 
 Overweight 
 Obese I 
 Obese II 
Fasting blood glucose (mg/dL) 
20 
 4 (20%) 
 10 (50%) 
 6 (30%) 
 
 10 (50%) 
 3 (15%) 
 4 (20%) 
 3 (15%) 
35,75 (5,68) 
 
 
 
24,85 (4,37) 
 
 
 
 
104,80 (4,25) 
Blood glucose 2 hours OGTT (mg/dL)  121,70(23,10) 
 
Kolmogorov-Smirnov test found that data of levels HOMA-IR and HOMA-B in 
prediabetic patient were in normal distribution (p>0.05). On prediabetics patients, mean of 
HOMA-IR was 4,12 (3,17) and mean of HOMA-B was 188,31 (155,13). Normal levels for 
HOMA-IR is less than 2.0, and for HOMA-B is 107 or more. 
 
4. Discussion 
Insulin resistance started dysglycemic state in prediabetic and type 2 diabetes mellitus. 
Cobb et al.(2013) stated that insulin resistance is a predictor of risk of metabolic syndrome 
and cardiovascular disease [11]. Tang et al.(2015) stated that insulin resistance is an important 
factor in prediabetic pathophysiology. So, assessment of insulin resistance by using HOMA-
IR is the key for primary prevention of diabetes dan nowadays it has been a part of screening 
guideline in high risk group [12]. 
  
 
 
 
In this study, we found mean of HOMA-IR level at 4,12 (3,17) in prediabetic patient. This 
is in accordance with Aguirre et al. (2012) who concluded that the level of HOMA-IR in 
prediabetic group consist of IFT group 4,53 (3,82) and IGT group 4,24 (3,21) [13]. The 
increase of insulin resistance in this study is in accordance with studies conducted by Nguyen 
(2010) and Mohtarin et al. (2016). Mohtarin et al. concluded that HOMA-IR level is higher in 
prediabetic compared to normoglycemic group[14], while Nguyen et al. stated that HOMA-IR 
level is significantly higher in prediabetic compared to normoglycemic groups [15]. 
Wallace et al. (2004) said that beta cell dysfunction is the decrease of its function as seen 
from abnormal beta cell response to blood glucose concentration [16]. In our study, the mean 
of HOMA-B level was 188,31 (155,13) in prediabetic patient. This was in accordance with 
Aguirre et al. (2012) who concluded that mean HOMA-B level in prediabetic group was 169 
(164) [13]. The increase of HOMA-B in our study is in accordance with works by Mohtarin’s 
(2016) and Owei’s (2017). Mohtarin et al. (2015) stated that HOMA-B level was significantly 
higher in 32 prediabetic patients (135) compared to 30 normoglycemic group (125) [14]. Owei 
et al. (2017) found that mean HOMA-B level was significantly higher in prediabetic patients, 
132 (57,1) compared to normoglycemic group, 62,4 (62,7) [17].  
Koh (2017) said that calculation of HOMA-B shows increase of insulin secretion when 
random blood glucose level is 180 mg/dL or more. HOMA-B level should be interpreted 
together with HOMA-IR. This is because increasing insulin sensitivity or decreasing insulin 
resistance will decrease HOMA-B, which does not reflect the failure of beta cell function [18]. 
 
5. Conclusion 
Assessment of HOMA-IR and HOMA-B in 20 prediabetic patients showed that they 
underwent increasing HOMA-IR which was compensated for by increasing HOMA-B. 
References 
[1]  El Din U, Mona M, Dina O.: Uric Acid in the Pathogenesis of Metabolic, Renal, and 
Cardiovascular Diseases: A review. Egypt: CrossMark. p: 1-12 (2016). 
[2]  DeFronzo R, Roy E, Muhammad A.: Pathophysiologic Approach to Therapy in Patients With Type 
2 Diabetes. Texas: Diabetes Journals. p: 1-12 (2013). 
[3]  Matfin G, Richard E.: Advances in the Treatment of Prediabetes. USA: Ther Adv Endocrinol 
Metab. p: 1-10 (2010). 
[4]  Diabetes Research Wellness Foundation. What is Diabetes (2016) 
[5]  Pour O, Samuel D.: Prediabetes as A Therapeutic Target. Clinical Chemistry 57:2. p: 215-20 
(2011). 
[6]  Nasrul E, Sofitri.:Hiperurisemia pada Pradiabetes. DiaksesdalamjurnalAndalas ISSN: 2301-7406. 
(2012). 
[7]  Cobb J, Walter G, Klaus P, Pamela N, Eric B, James H, et al.:A Novel Fasting Blood Test for 
Insulin Resitance and Prediabetes. J Diabetes Aci Technol. p: 100-110 (2013). 
  
 
 
 
[8]  Sung K, Gerald M, Sun H.: Utility of Homeostasis Model Assessment of β-Cell Function in 
Predicting Diabetes in 12,924 Healthy Koreans. California: Diabetes Care. p: 200-2 (2010). 
[9]  Behary P, Ian F, Kevin C.: Indices of Beta-cell Function: Association with Diabetes Control in 
Patients with Type 2 Diabetes on Stable GLP-1 Agonist Treatment. UK: John Wiley and Son. p: 
202 (2014). 
[10]  International Diabetes Federation. Belgia (2017) 
[11]  Cobb J, Walter G, Klaus P, Pamela N, Eric B, James H, et al.: A Novel Fasting Blood Test for 
Insulin Resistance and Prediabetes. Journal of Diabetes Science and Technology. p:1-11 (2013). 
[12]  Tang Q, Xueqon L, Peipei S, Lingzhong X.: Optimal cut-off values for the homeostasis model 
assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research 
and prospects for the future China. Tang. p:380-5 (2015). 
[13]  Aguirre L, B. Aguirre, Garcia L.: Clinical Usefulness of HOMA-IR and Homa Beta Cell Indices 
for Diabetes Risk Evaluation, Uruguay: Centro de InvestigacionesEndocrinologicas. p: 1 (2012). 
[14]  Mohtarin S, Matiur R, Subrata K, Forhadul H, Iqbal A.: Study of Phase of Insulin Secretion in 
Prediabetes and Newly Diagnosed Type 2 Diabetes Mellitus. BSMMU. p: 85-90 (2016). 
[15]  Nguyen Q, Sathanur R, Ji-Hua X, Wei C, Gerald S.: Fasting Plasma Glucose Levels Within the 
Normoglycemic Range in Childhood as a Predictor of Prediabetes and Type 2 Diabetes Adulthood. 
The Bogalusa Heart Study. p:124-8 (2010). 
[16]  Wallace T, Jonathan C, David R.: Use and Abuse of HOMA Modeling. Diabetes Care. p: 1487-8 
(2004). 
[17]  Owei I, Nkiru U, Casey P, Jim W, Samuel D.: Insulin-sensitive and insulin-resistant obese and 
non-obese phenotypes: role in prediction of incident pre-diabetes in a longitudinal biracial cohort. 
BMJ. p:1-6 (2017). 
[18]  Koh A.: Assessing beta-cell function in patients with type 2 diabetes in clinical practice. 
Department of General Medicine, Sengkang Health, Singapore (2017). 
